Pharmaceuticals Africa

Africa Vaccine Adjuvants Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

Africa Vaccine Adjuvants Market Industry Trends and Forecast to 2034: Segmented by (Type, Application, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Africa · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $14.7 Mn Placeholder estimate
Estimate 2025 $16.2 Mn 1.7% of the global market
Projected 2034 $37.9 Mn 133.9% Adds $21.7 Mn over 9 forecast years
CAGR 2025–2034 9.9% Faster than 54% of 180 Pharmaceuticals markets here
Key players 5
  • Africa is 1.73% of the global market.
  • Among regions, the largest is North America at $504.4 Mn.
  • Fastest growing: Africa (this report) at 9.9% a year.
  • Africa ranks 6th of 6 by size among regions.

Market size projection

Africa

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$21.7 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Vaccine Adjuvants Market market size by year, Africa
YearMarket sizeChange that yearSince 2025
2024 (estimate) $14.7 Mn — —
2025 (base) $16.2 Mn +$1.5 Mn —
2026 (forecast) $17.8 Mn +$1.6 Mn +9.9%
2027 (forecast) $19.5 Mn +$1.8 Mn +20.8%
2028 (forecast) $21.5 Mn +$1.9 Mn +32.7%
2029 (forecast) $23.6 Mn +$2.1 Mn +45.9%
2030 (forecast) $25.9 Mn +$2.3 Mn +60.3%
2031 (forecast) $28.5 Mn +$2.6 Mn +76.2%
2032 (forecast) $31.3 Mn +$2.8 Mn +93.6%
2033 (forecast) $34.4 Mn +$3.1 Mn +112.8%
2034 (forecast) $37.9 Mn +$3.4 Mn +133.9%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Africa Vaccine Adjuvants Market Analysis at a glance
Market size, 2025$16.2 Mn placeholder estimate
Forecast, 2034$37.9 Mn placeholder estimate
Growth (CAGR), 2025–20349.9% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsType and application (see all)
Key playersGSK PLC, Novavax, Croda International PLC, SEPPIC (Air Liquide), Dynavax Technologies (see all)
Regulator in AfricaAMASource: African Union, African Medicines Agency treaty. Checked 14 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Africa Vaccine Adjuvants Market Analysis Executive Summary

Vaccine adjuvants are ingredients added to vaccines to make the immune response stronger and longer-lasting.

Key segments of the vaccine Adjuvants market include type (Aluminum Salts, Emulsions and Saponin-Based) and application (Human Vaccines and Veterinary Vaccines).

Bar chart: Africa Vaccine Adjuvants market size, 2024–2034, placeholder estimates. $14.7 Mn in 2024, $16.2 Mn in 2025 and $37.9 Mn in 2034, 9.9% CAGR.
Africa Vaccine Adjuvants market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Africa Vaccine Adjuvants Market Dynamics

Market Growth Drivers

More surgery and intensive care, rising infection risks, new specialty medicines and the growth of hospital pharmacy services are driving the vaccine Adjuvants market.

Opportunity

Ready-to-use formulations, biosimilars and supply security programmes give the vaccine Adjuvants market room to grow.

Market Restraints

Drug shortages, price controls, generic competition and strict hospital budgets hold back the vaccine Adjuvants market.

Competitive Landscape for Vaccine Adjuvants Market in Africa

The vaccine Adjuvants market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Vaccine Adjuvants Market in Africa

Vaccine Adjuvants in Africa: rules and payment

The African Medicines Agency (AMA), set up by an African Union treaty in force since November 2021, aims to bring the work of national regulators together.⁠[1] In some of the countries we cover here, medicines are approved by EDA (Egypt)⁠[2], PPB (Kenya)⁠[3], SAHPRA (South Africa)⁠[4] and NAFDAC (Nigeria)⁠[5]. How care is paid for in some of these countries: universal health insurance (Egypt)⁠[6], the SHA (Kenya)⁠[7], planned National Health Insurance (South Africa)⁠[8] and out of pocket and the NHIA (Nigeria)⁠[9].

[1] African Union, African Medicines Agency treaty. Checked 14 Nov 2026.

[2] Egyptian Drug Authority. Checked 14 Nov 2026.

[3] Pharmacy and Poisons Board. Checked 14 Nov 2026.

[4] South African Health Products Regulatory Authority. Checked 14 Nov 2026.

[5] NAFDAC. Checked 19 Nov 2026.

[6] Universal Health Insurance Authority. Checked 14 Nov 2026.

[7] Social Health Authority. Checked 14 Nov 2026.

[8] National Department of Health. Checked 14 Nov 2026.

[9] National Health Insurance Authority (NHIA). Checked 19 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for vaccine Adjuvants. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Africa.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Vaccine Adjuvants right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Vaccine Adjuvants in context

Free data on this topic

Quick answers

Frequently asked questions

How big is the Vaccine Adjuvants market in Africa?
Placeholder estimate: about $16.2 Mn in 2025, rising to about $37.9 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Vaccine Adjuvants market in Africa growing?
Placeholder estimate: about 9.9% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Vaccine Adjuvants market report cover?
The report splits the market by type (Aluminum Salts, Emulsions, Saponin-Based, TLR Agonists) and application (Human Vaccines, Veterinary Vaccines).
Who are the key players in the Vaccine Adjuvants market?
Key players include GSK PLC, Novavax, Croda International PLC, SEPPIC (Air Liquide) and Dynavax Technologies.
What is driving the Vaccine Adjuvants market?
More surgery and intensive care, rising infection risks, new specialty medicines and the growth of hospital pharmacy services are driving the vaccine Adjuvants market.
Who regulates Vaccine Adjuvants in Africa?
The African Medicines Agency (AMA), set up by an African Union treaty in force since November 2021, aims to bring the work of national regulators together. Source: African Union, African Medicines Agency treaty. Checked 14 Nov 2026.
How much research is published on Vaccine Adjuvants?
PubMed lists 807 papers on Vaccine Adjuvants added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Africa

See all

Related on vaccines and biologics and biosimilars

See the topic